Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012

16 Feb 2012

• By Cathy Kelly

Related Content

MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012

11 Aug 2011

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

21 Nov 2011

Related Companies

Regeneron Pharmaceuticals, Inc.

Additional Topics

United States Reimbursement BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.